Search
Mosunetuzumab
go.drugbank.com/drugs/DB15434ApprovedInvestigational[L42245] In January 2023, the FDA granted accelerated approval to intravenous mosunetuzumab based on response rate. … [L44562] and in December 2025, the subcutaneous formulation was approved for the same indication. [L54848]
Casein
go.drugbank.com/drugs/DB10516ApprovedCasein allergenic extract is used in allergenic testing.
Categories: Compounds used in a research, industrial, or household settingCosibelimab
go.drugbank.com/drugs/DB15770ApprovedInvestigationalOn December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the … Cosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1).
Ciclesonide
go.drugbank.com/drugs/DB01410ApprovedInvestigationalCiclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
Picolinic acid
go.drugbank.com/drugs/DB05483ExperimentalPicolinic acid has been shown to be an anti-viral in vitro and in vivo, and sometimes works in conjunction with other cytokines such as interferon gamma to affect immune responses. … PCL-016 plays a key role in zinc transport.
Categories: Compounds used in a research, industrial, or household settingPicric acid
go.drugbank.com/drugs/DB03651ApprovedUsed as antiseptic, astringent, and stimulant for epitheliazation.
Categories: Compounds used in a research, industrial, or household settingInfluenza B virus B/Massachusetts/2/2012 hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14390ApprovedInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: AGRIPPAL 2.5 ML IM/SC ENJ.ICIN SUS.ICEREN KUL.HAZIR ENJEKTORMecasermin rinfabate
go.drugbank.com/drugs/DB14751ApprovedInvestigationalMecasermin rinfabate is similar to [DB01277] in that both drugs contain recombinant DNA origin insulin-like growth factor 1 (IGF-1). … Mecasermin rinfabate is approved for severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH)[A176020].
Synonyms: rhIGF-I/rhIGFBP-3, Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3Pacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigationalhas made it a desirable therapeutic target in MF treatment. … of both primary and secondary MF in patients with platelet counts < 50 x 10<sup>9</sup>/L.
Damoctocog alfa pegol
go.drugbank.com/drugs/DB14700ApprovedInvestigationalin patients diagnosed with Haemophilia A. … In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval.